I had thought these types of treatment had gone by the wayside in treatment during the last year of life. According to an Medscape article they have not. “‘Physicians should carefully consider whether the prescribed drugs are likely to achieve their benefit within the patient’s remaining lifetime,’ the authors concluded. The study included 151,201 patients ages 65 years and older who died in Sweden at a mean age of 81.3 years from 2007 to 2013. ‘The use and cost of preventive drugs during the last 12 months of life were the main study outcomes.’ The drugs of ‘questionable benefit’ assessed in the current study included antidiabetic drugs, antihypertensives, statins, and bisphosphonates medications for the treatment of chronic anemia and vitamin and
Topics:
run75441 considers the following as important: cancer treatment, Healthcare, Hot Topics, pharma
This could be interesting, too:
NewDealdemocrat writes March JOLTS report: declines in everything, fortunately including layoffs
NewDealdemocrat writes Manufacturing treads water in April, while real construction spending turned down in March (UPDATE: and heavy truck sales weren’t so great either)
NewDealdemocrat writes Repeat home sale prices accelerated in February (but don’t fret yet)
NewDealdemocrat writes Looking at historical “mid cycle indicators” – what do they say now?
I had thought these types of treatment had gone by the wayside in treatment during the last year of life. According to an Medscape article they have not.
“‘Physicians should carefully consider whether the prescribed drugs are likely to achieve their benefit within the patient’s remaining lifetime,’ the authors concluded. The study included 151,201 patients ages 65 years and older who died in Sweden at a mean age of 81.3 years from 2007 to 2013. ‘The use and cost of preventive drugs during the last 12 months of life were the main study outcomes.’ The drugs of ‘questionable benefit’ assessed in the current study included antidiabetic drugs, antihypertensives, statins, and bisphosphonates medications for the treatment of chronic anemia and vitamin and mineral supplements.’
Receipt of these long term preventative drugs added 20% to the cost of treatment during the final year of life. ‘The median drug cost during the last year of life was $1,482 (interquartile range $700-$2,896).'”